+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 90Years
All Genders
ID07830225

Pilot Study Using ctDNA to Guide Duration of Immune Checkpoint Inhibitor Therapy in Advanced Melanoma

Led by Rutgers, The State University of New Jersey · Updated on 2026-09-21

35

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of circulating tumor DNA ctDNA to guide the duration of immune checkpoint inhibitor ICI therapy in patients with unresectable or metastatic melanoma who show disease control or response to treatment. This phase II pilot study aims to determine if ctDNA levels can help decide when to stop or shorten ICI treatment, especially after at least 6 to 12 months of therapy. The study includes patients who have responded to treatment or experienced immune-related side effects requiring treatment interruption. Participants with undetectable ctDNA and disease control will stop ICI therapy after one year. Those who have immune-related adverse events but undetectable ctDNA may also stop treatment. Patients with detectable ctDNA at the decision point will continue treatment per the investigators choice. If ctDNA becomes detectable during monitoring, restarting ICI may be considered based on imaging and clinical factors. Monitoring with imaging and ctDNA tests occurs every three months after treatment discontinuation. Throughout the study, participants will undergo regular imaging and ctDNA assessments to track disease status and treatment response. The primary outcome is the rate of sustained ctDNA negativity 12 months after stopping ICI. Secondary outcomes include progression-free survival, overall survival, and treatment-free survival one year after discontinuation. The study involves adults aged 18 to 90 with advanced melanoma and lasts until June 2029, including ongoing monitoring after treatment decisions.

CONDITIONS

Brief Title

A Pilot Study of ctDNA-Guided Immune Checkpoint Inhibitor Duration in Patients With Advanced Melanoma.

Research Team

S

Sarah Weiss, MD

O

Olutobi Adewale

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here